Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and related technologies in the Americas, Australia, the Asia Pacific, Europe, and the Middle East. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients’ physiological data; Somté PSG; Grael PSG; Grael 4K PSG; Falcon PSG; Falcon HST; and Somté, an investigative tool. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG, Grael 4K-EEG, and Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, a portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, it provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; CURRY, a signal processing and source localization multi-modal neuroimaging suite; Profusion neXus Scheduler for planning for staff and time; Somte and Persyst Software; HD Digital Video; Profusion Plus; ECG Free software; and TCM5 FLEX Transcutaneous Monitor, Grael DC, Siesta extended battery pack, and Summit IP products. Further, the company offers magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; and consumables and supplies for diagnostic and research solutions. Additionally, the company provides doppler diagnostic products; Nuevo LTM EEG; Orion LifeSpan MEG; and quik-cap EEG electrode arrays. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.
Metrics to compare | CMP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −60.6x | −5.7x | −0.7x | |
PEG Ratio | 0.20 | 0.01 | 0.00 | |
Price/Book | 3.5x | 3.1x | 2.6x | |
Price / LTM Sales | 1.5x | 6.8x | 3.4x | |
Upside (Analyst Target) | 138.8% | 59.6% | 37.7% | |
Fair Value Upside | Unlock | 2.1% | 5.0% | Unlock |